产品介绍
Product Description
Application
BI 2536 may be used in targeting polo-like kinase 1 (PLK1) in cancer therapy; and studying its role in neuroblastoma.
Biochem/physiol Actions
BI 2536 is an ATP-competitive, potent and selective polo-like kinase 1 (Plk1) inhibitor (Plk1/2/3 IC50 = 0.83/3.5/9.0 nM; [ATP] = 7.5 µM) that induces mitotic arrest and apoptosis in human cancer cultures (EC50 <100 nM among 32 different cancer lines) and suppresses human cancer xenografts tumor growth in nude mice in vivo (50-60 mg/kg i.v. twice weekly on two consecutive days; HCT116 and NCI-H460).
技术参数
Specifications
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | -10 to -25°C |
| SMILES string | O=C(NC1CCN(C)CC1)C2=CC=C(NC(N=C3N(C4CCCC4)[C@@H]5CC)=NC=C3N(C)C5=O)C(OC)=C2 |
